Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants
about
Contributions of human enzymes in carcinogen metabolismGlucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sitesUDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility.High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivativesSULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer PatientsFirst-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.Interindividual differences in phytochemical metabolism and dispositionIdentification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility.Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention.Differences in metabolite-mediated toxicity of tamoxifen in rodents versus humans elucidated with DNA/microsome electro-optical arrays and nanoreactors.Interindividual differences in response to plant-based diets: implications for cancer risk.Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolitesPotential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.Glucuronidation of tobacco-specific nitrosamines by UGT2B10Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Transcriptional regulation of human UDP-glucuronosyltransferase genes.UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population.Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.Screening of multiple hormonal activities in surface water and sediment from the Pearl River system, South China, using effect-directed in vitro bioassays.Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
P2860
Q30520640-59AB1BBF-3B8F-4278-8B5D-5F2190FE9504Q33714571-49DBF180-0BC3-4F64-A305-896F5326DA2BQ33714575-8B0B60EA-F0A9-4A93-82B4-1512340FFA15Q34044936-3152CF5D-3DE9-454D-B1BD-A354F38B558EQ34125047-AAC1ACC3-E350-4876-8CF4-65E746265BAAQ34307873-BE5D63A7-22D6-417A-9B77-D16FBA086F8DQ34774040-4AC45EFF-84D1-40EE-9AEF-36E070ECDEBBQ35008045-1406D008-5398-4FCD-8F14-2C4B0FC20D0AQ35691825-78F505D9-3D0A-4CB5-AF8E-6C34A702F809Q36132293-8F45581B-57F0-4452-B9F6-C0713E0E2561Q36148997-DBBC064A-013F-4610-B3EE-54E6A27BC7ACQ36406279-74CF7138-BAE6-4F1B-9990-9F9A64645B2BQ37000698-F8DE4E6B-AE2D-4A70-96A5-EB67C2BC9800Q37133759-60A372D3-A1A5-4DA4-9277-C04780B9B9ABQ37179160-2F6F1DA1-6D0A-466D-8E46-1CF3C77F36B5Q37195375-A6FF38A2-D5B8-44A0-A092-971FE9C08B19Q37221922-628C2118-DF29-4F0B-B0EB-38B94478270EQ37271209-444FE2BA-7422-42BB-9CD7-DD7A504C15F3Q37271799-06DD7017-D03A-424A-8903-690DA9B5181AQ37663398-75DC79D5-12C4-408D-9C38-555F6BBFF72CQ38030052-6E4AACBC-D656-444D-B510-7176F6A4101FQ38103593-041C573B-5F78-419A-A635-DB7559D96DE5Q38105253-F1F12AF2-440B-4D96-A8B4-ADEE91CB4763Q38261875-81A37299-6298-46E8-8BC9-1EEF9F33B096Q39647877-A3CC9BB1-EFD9-4BB8-9DDE-C3CDF23D3A3DQ39868674-7BA2C743-C84A-466A-A8EF-566CFE6DBDE8Q40789462-66A3DD0F-CCB9-4182-9FD9-50F2AC90064CQ45153204-A7C32E45-E2FD-41AD-9F27-7252A69EDE29Q48334328-EE626DD3-5E4E-4F09-8F36-6FE87107D100Q52613905-9BDB3FC3-BE2F-4744-A678-CE1648396A58Q57072034-D18DF07D-7408-4545-AFC2-A88690BD5810
P2860
Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Characterization of tamoxifen ...... ation by human UGT1A4 variants
@ast
Characterization of tamoxifen ...... ation by human UGT1A4 variants
@en
type
label
Characterization of tamoxifen ...... ation by human UGT1A4 variants
@ast
Characterization of tamoxifen ...... ation by human UGT1A4 variants
@en
prefLabel
Characterization of tamoxifen ...... ation by human UGT1A4 variants
@ast
Characterization of tamoxifen ...... ation by human UGT1A4 variants
@en
P2093
P2860
P356
P1476
Characterization of tamoxifen ...... ation by human UGT1A4 variants
@en
P2093
Dongxiao Sun
Jia-Long Fang
Kimberly Duncan
Philip Lazarus
Ryan W Dellinger
P2860
P2888
P356
10.1186/BCR1539
P577
2006-01-01T00:00:00Z
P5875
P6179
1022284965